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EDITORIAL
Delivering cancer care: a model from the West Midlands
DJ Kerr', R Griffiths2 and B Edwards2
'CRC Institutefor Cancer Studies, University ofBirmingham, Birmingham B15 2TH; 2West Midlands Regional Health Authority,
Arthur Thomson House, Hagley Road, Edgbaston, Birmingham B16 9PA, UK.
Recent publication of a discussion document by an Expert
Advisory Group on Cancer Services commissioned by the
Department of Health's ChiefMedical Officer, has provided a
much needed focus on this aspect of health care delivery.
This was precipitated, at least in part, by a series of rather
stark comparisons of age-specific mortality rates for a range
of cancers, in which the UK fared relatively poorly. These
data, gathered from population-based cancer registries, are
complex and conceal a number of contributory factors, such
as differential case mix, later stage of presentation and
inequity of access to quality, multidisciplinary cancer care.
Clearly, the solution to narrowing the survival gap between
the UK and the leading European nations will depend upon
which of these factors predominates and would determine at
which point we would invest resources in the continuum of
cancer care, e.g. screening, patient education, primary or
secondary healthcare. Current research driven through audit
and more detailed survey of the cancer registry data will help
to unpick this Gordian knot, but it is likely that an important
component of the survival difference is caused by inequities in
the delivery of cancer care.
The West Midland Regional Health Authority (WMRHA)
serves a population of 5.3 million and has one academic
oncology centre, based within the University of Birmingham's
CRC Institute for Cancer Studies. Following discussion at
the Regional Medical Executive, a Cancer Services Working
Group (CSWG) was established with a remit to provide a
blueprint for cancer services in the West Midlands. The
CSWG consists of the clinical directors of the four putative
cancer centres and specialist physicians and surgical
oncologists from around the region who have national and
international standing in their respective clinical subspecial-
ties. The first draft of the document was sent out for region-
wide consultation in January 1995, and a series of meetings
was held with purchasing chief executives, health care
professionals, directors of public health in each of the 26
district health authorities and trust managers in order to
refine the document and generate a sense ofjoint ownership.
The final version of the cancer plan was published by the
health authority in July 1995.
A five-tier service is envisaged which is broadly in keeping
with the definitions outlined in the Calman discussion
document (Table I). In this hub and spoke model linking
cancer centres and units (Figure 2), the regional cancer centre
serves the following additional functions:
1. Provision of a high-quality basic research facility
integrated into the clinical service to ensure the continual
application of science to cancer management.
2. A focus for the introduction of novel therapies from the
laboratory to the clinic.
3. The capacity to design, construct, implement and
monitor cancer treatment trials at all levels of complexity,
e.g. phase, I, II and III, local, national and international
studies.
4. Education of healthcare professionals, patients, their
carers and the lay public.
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One further area in which the West Midlands deviates a little
from the Calman document is the designation of an associate
cancer centre. It is envisaged that highly specialised surgical
and other services will normally be provided in the cancer
centres. However, given the current 'map' of service provision
in the West Midlands, there will also be a need for certain
specialised surgical services to be provided in hospitals that
would not meet the full criteria to enable designation as a
cancer centre. This is to take account of existing, predomi-
nantly surgical, expertise within the region, which is already
established in District General Hospitals that will be defined as
cancer units rather than cancer centres. Some of these highly
specialised services already exist in the region, such as thoracic
surgery at the Birmingham Heartlands Hospital NHS Trust
and oncology orthopaedic surgery at the Royal Orthopaedic
Hospital NHS Trust, paediatric oncology services co-ordinated
by the Birmingham Children's Hospital NHS Trust. There will
need to be close and defined links between the 'associate cancer
centres' and the 'cancer units/centres' with which they are
linked to ensure that the multidisciplinary ethos prevails. The
purist might argue that all cancer specialists who are involved
in providing a central or regional service should be relocated,
with appropriate infrastructural support, to the cancer centres.
However, in our view, this is unlikely and a more pragmatic
approach, in the short and medium term is to recognise,
appraise and utilise existing services.
We wish to create an integrated cancer service which will
allow access to a flexible but homogeneously excellent cancer
service across the length and breadth of our region. Mindful
of the need for audit and a desire to demonstrate that
service reorganisation will meet the needs of our community
and will result in manifest good (improvements in quality of
life and survival) we have commissioned an IT network to
bind the cancer centres and satellite units together. This will
be based in the Regional Cancer Registry and will provide
an important database to monitor the quality of service
provision. If we accept that our interpretation of the Cancer
Services report is that it suggests a hypothesis to test,
namely, by delivering improved cancer services we will
reduce cancer mortality, then the regional IT network will
provide the baseline data required to prove or refute this
base concept.
Predicant philosophy
We have described the structure of the envisaged cancer
service in the West Midlands, but what of its operating
policy? This is built upon four separate but related planks:
1. Surgical site specialisation
There are several studies published which show wide
interindividual variation in surgical outcome for a range of
tumour types, which have been retrospectively matched for
stage and other prognostic variables (McArdle and Hole,
1991; Hakama et al., 1989; Gillis et al., 1991; Edge et al.,
1993; Matthews et al., 1986). The quality of these data is not
as high as would occur, say, from a randomised study
comparing survival following operation by surgical class ADelivering cancer care
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(somehow designated expert) vs surgical class B (somehow
designated less expert). However, such a study would lead us
into an ethical minefield and it would be difficult to envisage
patients entering such a trial with fully.informed consent.
Therefore we have to interpret existing data with caution,
mindful that it is the best available. In the West Midlands we
have decided to test the 'golf' hypothesis: that those surgeons
who perform the operation frequently. have a better
opportunity to develop a low handicap and 'hit the target
green' more often than their high-handicapped, less practised
colleagues. We realise that arguments could be made that
there are highly skilled individuals who can turn their hand
to any operation at any time, however, given the fact that we
wish to establish multidisciplinary teams, it would seem more
likely that this could be more easily accomplished by asking
our surgical colleagues to reorganise their workload so that
they can meet minimum caseload criteria for individual
diseases and establish a critical mass for training juniors as
described by our experts on the CSWG.
2. Multidisciplinary teams
The weight of evidence, admitting again that it suffers from
the lack of randomised trials previously outlined, supports
the concept that there are better outcomes for cancer patients
if they are treated in comprehensive cancer centres which
offer surgical and non-surgical site specialisation, case
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conferences, joint or simultaneously adjacent clinics, con-
sistent referral patterns and adequate sessional commitment
of non-surgical oncology (Basnett et al., 1992; Davis et al.,
1987).
3. Clinical guidelines
Like the IT network, we envisage that consensually agreed,
clinical guidelines will be a further factor which will 'glue' the
cancer network together. Members of the CSWG have
formed clinical disease-specific subgroups comprising sur-
geons, radiotherapists and physicians from around the region
to develop guidelines within an approved framework which
will be 'purchaser-friendly', auditable and jointly owned.
There is a pressure to develop national guidelines, and several
members of our regional CSWG serve on national
committees. We felt it important to push ahead and generate
regional guidelines as uptake of these would seem more likely
if there was a real sense of local 'ownership' rather than a
feeling of central coercion (Davis et al., 1985).
4. Infrastructural support
The therapeutic team should be consultant-led, but cannot
exist without appropriate infrastructural support and the
guidelines clarify the level of service provision required for
radiology, pathology, pharmacy and nursing services.
Terminal and palliative care services
(community-based)
Death
Figure 1 The pathway of cancer care. The risk of cancer is
determined by the interplay between environmental and genetic
factors.
:Coventry
Figure 2 The West Midlands cancer network.
Table I Five levels of care for cancer sufferers are proposed
1. Primary care is seen as the focus of care. Detailed discussions between primary care teams, units and centres will be necessary to clarify
patterns of referral and follow-up which will ensure the best outcomes.
2. Cancer units should be created in many District General Hospitals. These should be of a size to support clinical teams with sufficient
expertise and facilities to manage the more common cancers.
3. Associate cancer centres will be accredited for the management of specific cancer types or therapeutic procedures, e.g. thoracic surgical
oncology services, paediatric oncology services, but will not meet the full criteria for a cancer centre.
4. Cancer centres should provide expertise in the management of all cancers, including common cancers, within their immediate
geographical locality and less common cancers by referral from cancer units. They will provide specialist diagnostic and therapeutic
techniques including radiotherapy.
5. Regional cancer centre fulfils the functions described in section 4, but has additional roles ofintegrating laboratory and clinical research,
co-ordinating clinical trials and continuing education.D can cam
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We have the blueprint; we have clinical support; we have
political will; so how will we implement the change? The
Regional Medical Executive has formed a Cancer Task
Force, chaired by the Regional Medical Director, which
comprises a senior cancer clinician, a regional nurse, a
senior purchaser, a patient representative, a public health
clinician, the Deputy Director of the Cancer Registry, a
representative from the NHSE outpost and two adminis-
trators. Each Trust that wishes to be designated a cancer
centre or unit has been asked to submit a business case to
the Cancer Task Force showing how it will fulfil the
requirements of the blueprint. The team will then site visit
these hospitals at intervals over the next 12 months and,
working with the purchasers, will appraise each case to be
considered as a centre or unit. If deficiencies in the service
are identified then the Trust and the team will negotiate a
timetable for change and rectification of problems. Provision
of the regional IT network will allow consensual, region-
wide audit and provision of baseline data on cancer
incidence and mortality which will allow us to monitor the
impact of these service changes. We envisage that this
process of appraisal will be continuous with a site visit
frequency of once every 2 years.
What else needs to happen?
Primary healthcare
This is a relatively neglected area and much needs to be done
here. Preliminary ideas include diagnostic algorithms to
strengthen GPs index of suspicion for cancer (Austoker,
1994), provision ofcommunity cancer liaison officers, perhaps
GPs or nurses with an attachment to the cancer centre or
unit, open access to early diagnostic facilities, shared follow-
up protocols for cancer patients once active treatment has
ceased, and a clearer definition of the role of the GP in
palliation.
Contracts
Should they be held by the centre and subcontracted to units,
or is it easier for purchasers to contract locally and have
defined agreements with the cancer centres? Will contracts be
made with multidisciplinary teams, so that a whole section of
the cancer continuum can be purchased? Given the strong
arguments that have been presented, can a logical approach
be made to treasury for new, ring-fenced funding to be made
available to purchasers to fund the service changes envisaged
in this paper? This work is being approached within the West
Midlands, through the regional office, and it is likely that a
number of different purchasing models will be used.
Training
There is an obvious international discrepancy with inequities
in non-surgical oncology staffing. For example, there are only
70 (including academic staff) consultant medical oncologists
in the UK, compared with 10 000 board-certified medical
oncologists in the USA and one consultant clinical oncologist
(radiotherapy base) per 224 000 of the population compared
with, say, France with an average of one radiotherapist per
110 000 of the population, i.e. twice the number of cancer
specialists.
These discrepancies need to be approached, probably
centrally, in terms of providing additional training posts,
which would feed into established consultancies. Alterna-
tively, perhaps we need a more radical look at job structures
and the role of the consultant within a multidisciplinary
team.
It would seem that time, tide and wind are favourably set for
a shift in the organisation of cancer services. Let us test the
hypotheses outined in this brief paper and see if these
changes will bring about demonstrable benefit.
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